Inhaled bronchodilators for cystic fibrosis
Authors:
- 11 February 2016
- journal article
- retraction
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (2) , CD003428
Abstract
This review has been withdrawn because it has been split into the following reviews: 'Long‐acting inhaled bronchodilators for cystic fibrosis' and 'Short‐acting inhaled bronchodilators for cystic fibrosis'.Keywords
This publication has 40 references indexed in Scilit:
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effectiveness and tolerability of high‐dose salmeterol in cystic fibrosisPediatric Pulmonology, 2002
- Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: Double‐blind, placebo‐controlled crossover study in cystic fibrosisPediatric Pulmonology, 2001
- Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosisEuropean Journal of Pediatrics, 1996
- Short‐term and long‐term effects of albuterol aerosol therapy in cystic fibrosis: A preliminary reportPediatric Pulmonology, 1995
- Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin‐induced bronchoconstrictionPediatric Pulmonology, 1993
- Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosisPediatric Pulmonology, 1992
- A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivityJournal of Allergy and Clinical Immunology, 1990
- Immediate Effect of Various Treatments on Lung Function in Infants with Cystic FibrosisRespiration, 1989
- Mechanisms of bronchial hyperreactivity in cystic fibrosisPediatric Pulmonology, 1988